Skip to main content
CMG Pharmaceutical Co., Ltd. logo

CMG Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 058820 ISIN · KR7058820002 KO Manufacturing
Open in API
Filings indexed 165 across all filing types
Latest filing 2023-03-24 Board/Management Inform…
Country KR South Korea
Listing KO 058820

About CMG Pharmaceutical Co., Ltd.

http://www.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development of advanced drug delivery systems. The company's core competency is its Oral Thin Film (OTF), or Orally Dissolving Film (ODF), technology platform. This technology is used to develop improved new drugs, new formulations, and combination therapies designed to enhance patient convenience and efficacy. The company's portfolio includes prescription medications and general pharmaceuticals. As an affiliate of CHA Health Systems, CMG Pharmaceutical is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details changes to the board of directors, specifically the appointment of an outside director. According to the filing definitions, announcements regarding changes in the company's board of directors are classified as 'MANG' (Board/Management Information).
2023-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from CMG Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data, and auditor information for the fiscal year. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and filing of the audit report, rather than the full annual report itself. Therefore, it is classified as an Audit Report/Information document. FY 2022
2023-03-16 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for CMG Pharmaceutical Co., Ltd. for the 22nd fiscal year (2022). It contains comprehensive financial statements, management discussion and analysis, governance information, and operational details. This document is the Korean equivalent of an Annual Report (10-K) as it covers the full fiscal year and provides detailed financial and business performance data. FY 2022
2023-03-16 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by CMG Pharmaceutical. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, proxy solicitation details, and agenda items (such as financial statement approval). This document is specifically designed to solicit votes from shareholders for the AGM, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2023-03-10 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (CMG Pharmaceutical) regarding a correction to a previously disclosed financial statement (a '30% change in revenue or profit/loss' report). It details specific line-item adjustments to net income and assets following an external audit. Since this is a formal regulatory disclosure of financial data updates rather than a full annual report, a conference call transcript, or a simple announcement of a report's availability, it falls under the category of general regulatory filings. FY 2022
2023-03-07 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for CMG Pharmaceutical. It outlines the date, location, and specific agenda items (financial statement approval, director/auditor appointments, and remuneration limits). This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2023-03-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.